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Abstract 
Degree project in Medicine 
Freeze-Dried Plasma and Adverse Events 
Johannes Forsberg 
Programme in Medicine, Sahlgrenska Academy, Gothenburg, Sweden, 2019 
 
Introduction: Freeze-dried plasma (FDP) is a pulverized form of blood plasma. FDP has many 
advantageous characteristics and can be used to correct coagulopathy or as a volume expander. 
Packed red blood cells (PRBC) are erythrocytes used for transfusions and common indications 
are haemorrhage and anaemia. FDP and PRBC are crucial components for treatment of 
coagulopathic and haemorrhagic patients.  
 
Aim: The aim of this study was to investigate how different ratios of FDP and PRBC transfused 
to trauma patients during the initial patient care affect mortality, the number of days treated and 
the frequency of transfusion related complications, i.e. Acute Kidney Injury (AKI), Acute 
Respiratory Distress Syndrome (ARDS), Multiple Organ Dysfunction Syndrome (MODS) and 
Transfusion Related Acute Lung Injury (TRALI).  
 
Methods: The study was a retrospective descriptive analytical chart review for patients treated 
between 2018-01-01 to 2019-08-15 at the resuscitation unit and the trauma ICU at Inkosi Albert 
Luthuli Central Hospital, Durban, South Africa. Data was collected from a local database and 
electronic medical records. Fisher’s Exact Test and Pearson’s Chi-Squared Test was used to 
analyse the research questions. 
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Results: 73 patients were included in the study and divided into two groups with 35 patients in 
group A (FDP ≤ PRBC) and 38 patients in group B (FDP > PRBC). The number of patients 
that expired during the first two weeks in group A were 8 (7 patients during day 0-7 and 1 
patient during day 8-14) and 10 patients group B (5 patients during day 0-7 and 5 patients during 
day 8-14), resulting in a p-value of 0.152. In group A, the number of patients treated for 1-7 
days were 4, the number of patients treated between 8-14 days were 9 and the number of patients 
treated for 15 days or more were 11. The corresponding number of patients in group B for the 
three different categories in the same succession were 10, 8 and 9 patients respectively, 
resulting in a p-value of 0.277. Regarding transfusion related complications that occurred more 
than 24 hours after arrival, 4 patients developed AKIN, 0 patients developed TRALI, 1 patient 
developed ARDS and 5 patients developed ARDS. The number of patients who developed 
transfusion related complications were too small in order to perform analytical statistics. 
 
Conclusions: No significant differences between the groups were found regarding the three 
research questions. Additional studies with greater number of patients will be required to further 
evaluate the impact of different ratios of PRBC and FDP. 
 
Key words: Freeze-dried plasma, packed red blood cells, transfusions, trauma, adverse events 
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Abbreviations 
AIS: Abbreviated Injury Scale 
AKI: Acute Kidney Injury 
AKIN: Acute Kidney Injury Network 
ARDS: Acute Respiratory Distress Syndrome 
FDP: Freeze-Dried Plasma 
FFP: Fresh Frozen Plasma 
FLYP: French Lyophilized Plasma 
IALCH: Inkosi Albert Luthuli Central Hospital 
ISS: Injury Severity Score 
MODS: Multiple Organ Dysfunction Syndrome 
PRBC: Packed Red Blood Cells 
ROTEM: Rotational thromboelastometry 
TIC: Trauma-induced coagulopathy 
TICU: Trauma Intensive Care Unit 
TRALI: Transfusion Related Acute Lung Injury 
VAP: Ventilator-Associated Pneumonia 
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Background 
Introduction to the study 
This study was conducted in South Africa, which is one of the countries in the world which has 
highest injury burdens and highest injury-related mortality (1). In year 2017, the homicide rate 
in South Africa was 35.9 per 100,000 inhabitants, which in absolute numbers generates high 
quantities of homicides considering the approximately 58.7 million inhabitants (2, 3). Since 
FDP has been used since 1996 in considerable proportions in South Africa, there is wide 
experience and a great scientific foundation which promotes research on FDP. Considering the 
great numbers of trauma patients, the need for appropriate blood products, such as FDP, is 
therefore indispensable. The South African Blood Service has for a long time faced great 
challenges recruiting sufficient numbers of blood donors to fulfil the need for blood products 
(4, 5). The combination of the above-mentioned factors therefore demands optimal usage of 
blood products. Further knowledge about FDP and its effect could possibly optimize its usage 
and improve the treatment of trauma patients. Under the following subheadings in the 
backgrounds section, important physiological and pathological processes in trauma patients 
will be presented, as well as crucial components and factors in the treatment of trauma and their 
possible consequent complications. 
Haemostasis 
Haemostasis is the physiological process responsible for both clot formation and prevention of 
bleeding. Both procoagulant and anticoagulant processes are involved in the haemostasis. 
When the vascular system is intact, maintenance of blood fluidity is prioritized. If vascular 
damage occurs, clot formation is triggered in order to prevent loss of blood (6). These functions 
are elementary components for adequate physiological function and survival. Inadequate 
function of the haemostasis may therefore lead to disease or death (7). The formation of blood 
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clots is a complex mechanism involving both primary and secondary haemostasis. Primary 
haemostasis alludes to the cellular activity of the haemostasis, while the secondary haemostasis 
alludes to the activity of the coagulation cascade (8). In the primary haemostasis the platelets 
play a very central roll. If a vessel injury appears, platelets adhere to molecules on the exposed 
subendothelial extracellular matrices, thereby circumscribing blood loss. Adhesion, activation 
and aggregation are involved in the primary haemostasis. Aggregation which is the final step, 
signifies that a clot containing platelets and fibrinogen forms. (9, 10). The secondary 
haemostasis pathway consists of the coagulation cascade which leads to the formation of 
fibrinogen and fibrin (7). The different coagulation factors in the coagulation cascade are 
zymogens, inactive precursors, that can be activated and catalyse the activation of other 
coagulation factors. The coagulation cascade is divided into the intrinsic pathway, extrinsic 
pathway and common pathway. The intrinsic pathway is activated by damaged surfaces and the 
extrinsic pathway is activated by tissue factor. Both these pathway leads to the common 
pathway where the end product is fibrin. Fibrin finally integrates with platelets in a process 
called crosslinking which strengthens the clot and consequently prevents haemorrhage (6, 11). 
Anticoagulation is a process which inhibits coagulation and prevents thrombosis. Protein C 
which can be converted into activated protein C (APC), is one of many proteins involved in 
anticoagulation. Fibrinolysis is the process where blood clots are being broken down to enable 
normal blood flow. Fibrinolysis is activated by tissue plasminogen which converts plasminogen 
to plasmin. Plasmin then splits fibrin which resolves the fibrin clot (7). 
  
  
8 
Coagulopathy and haemorrhage 
Coagulopathy is defined as the lack of normal coagulation function. Trauma itself is a risk 
factor for coagulopathy, which the term trauma-induced coagulopathy (TIC) refers to (12). 
Chemically and physiologically, several pathological components like bleeding and tissue 
injury in the initial phase of trauma, contributes to inadequate balance of both procoagulant 
processes, anticoagulant processes and fibrinolysis. Multiple studies have suggested that 
protein C is involved in the development of TIC (12). Insufficient perfusion and bleeding cause 
exaggerated activation of protein C. As a result, excessive fibrinolysis and fast consumption of 
factors regulating haemostasis occurs (13). TIC is a clinical syndrome and multiple clinical 
factors can contribute to the arising of TIC (14). Five of these clinical factors that increase the 
risk for TIC are treatment with intravenous fluids, blood dilution, hypothermia, acidosis and 
insufficient perfusion (12). The lethal triad is a phenomenon which refers to hypothermia, 
acidosis and coagulopathy and how each of these factors affect and worsen the other factors. 
Hypothermia and acidosis respectively worsen coagulopathy. If both hypothermia and acidosis 
are present simultaneously, the deterioration of coagulation is more profound than the 
deterioration of each factor summed up (15). Rotational thromboelastometry (ROTEM) is a 
method that can be used to analyse coagulation status and detect coagulopathy. Different parts 
of the coagulation cascade can be analysed. INTEM is a test which screens the intrinsic pathway 
whereas EXTEM is a test that screens the extrinsic pathway. The results of different tests can 
be used as guidance for administration of fluids and blood products like platelets, plasma, 
cryoprecipitate or tranexamic acid (12). TIC can also contribute to haemorrhage and 
haemorrhagic shock. Haemorrhagic shock causes more than 500,000 deaths per year globally. 
Except for aiming to quickly control the bleeding source, transfusions with fluids or blood 
components are the preferred treatments for uncontrolled haemorrhage and haemorrhagic shock 
(16).  
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Injury Severity Score 
In trauma, a grading system called injury severity score (ISS), can be used to assess the severity 
of the injuries. The score is based on abbreviated injury scale (AIS). AIS grades injuries from 
0-6 (17). The ISS is calculated by using the square of the AIS and adding the square values 
from the three most seriously injured regions out of six specified body regions. A score of 6 on 
AIS in one of the 6 regions, by definition generates an ISS of 75 which is the highest possible 
ISS. Each body region can generate an injury severity score between 0-25, consequently 
generating a possible total injury severity score between 0-75, where a higher score correlates 
with more serious injuries (17, 18). 
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Freeze-dried plasma 
Plasma is a blood product which contain all clotting factors (19). Freeze-dried plasma (FDP) is 
pulverised form of blood plasma (20). FDP was developed during the 1930s and was used by 
the British and American forces during World War II. The blood plasma used for FDP can be 
obtained through separation or apheresis from whole blood and can be prepared through 
lyophilization or aerosolization. Lyophilization is the most common of the two processes and 
implies that plasma first is being frozen, whereupon the pressure is reduced and the temperature 
is slowly increased, resulting in pulverization of the plasma (4, 20, 21). FDP has many 
advantageous characteristics in military settings and harsh conditions. FDP is shelf stable for 
up to two years, can be stored in ambient temperatures, is easily transported and is ABO-
universal (21-23). FDP is easily rehydrated with sterile water and then stirred for three to five 
minutes to enable administration (20, 23). FDP can be used as a volume expander or to treat 
coagulopathy through substitution of depleted coagulation factors (24, 25). The production of 
FDP was for a period discontinued since transmission of viral diseases such hepatitis and HIV 
occurred too frequently (4, 21). Since the early 1990s and after however new methods have 
enabled FDP to be produced with considerably higher safety profiles. This led to re-
establishment of the FDP within the military (23), but also increased the interest to use FDP 
within the health care. In some parts of South Africa FDP has been used within the healthcare 
since 1996 (4), and in Bergen (Norway) and Gothenburg (Sweden) FDP has been used within 
the air medical service in the last few years (26). Currently there are at least three different 
producers globally who produce FDP with their own product names. The French Military Blood 
Institute produces the French lyophilised plasma (FLYP), the German Red Cross produces 
LyoPlas N-w and National Bioproducts Institute in Pinetown, South Africa, produces Bio 
plasma FDP (4).  
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Comparison of freeze-dried plasma and fresh frozen plasma 
FDP has traditionally mostly been associated with military use, whereas fresh frozen plasma 
(FFP), another form of plasma, has been more regularly used within the health care (4, 20, 21). 
FFP is obtained through separation or apheresis from the whole blood and is then within 8 or 
24 hours frozen and stored at -18 °C or colder for maximally one year. Regarding handling of 
FFP, this product must be stored frozen and has to be thawed in a water bath for at least 15 to 
20 minutes before administration is possible. Once thawed the FFP can be stored refrigerated 
for maximally 5 days before it expires (21, 23, 27). For FFP, these factors entail continuous 
access to storage in freezers and therefore contribute higher demands for storage than for FDP. 
Studies have tried to evaluate the effect of FDP compared to FFP and it has been shown that 
FDP is functionally equivalent compared to FFP (4, 21). FDP has equal levels of clotting factors 
and proteins compared to FFP after storage at ambient temperature for two years (23). In both 
in vitro and porcine injury models, FDP has shown equal coagulation profile compared to FFP 
as single treatment but also when combined with packed red blood cells in ratio 1:1 (21). The 
clotting factor activity however is slightly lower for FDP than for FFP, but it does not seem to 
contribute to clinical ineffectiveness or lose its coagulative effect in animal models. The risks 
of FDP are equal to them of FFP, namely allergic reactions and overtransfusion with side effects 
such as lung oedema. The prevalence of transfusion reactions is not considered higher for FDP 
than for FFP (20, 28). In a big study where FFP was compared towards LyoPlas N-w, the 
frequencies of transfusion reactions were 0.023% for FDP and 0.018% for FFP.(4). 
Blood products, fluids, calcium and magnesium 
Packed red blood cells (PRBC), or red blood cells, or, are erythrocytes separated from whole 
blood intended for transfusion (29, 30). PRBC can be used to increase the oxygen carrying 
capacity, to treat anaemia and haemorrhage, as part of treatment for TIC and as part of massive 
transfusions (more than 10 units of PRBC during 24 hours) (19, 31-35). A single unit of PRBC 
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can raise the haemoglobin levels 1 g/dl. For in-ICU patients with stable organ dysfunction, 
many studies have found beneficial aspects when the threshold for transfusions is set to 
haemoglobin levels of 7 g/dl (30), while for trauma patients undergoing resuscitation or being 
planned for surgery, the threshold for transfusions is set to haemoglobin levels of 10 g/dl (36). 
The patient’s clinical status and signs of anaemia are also important factors to consider. 
Platelets can be obtained from whole blood or apheresis (30). Platelets can be used in patients 
with thrombocytopenia or functional defects in the thrombocytes (19). Platelets can also be 
used as part of massive transfusions (31, 32). A single unit of platelets typically raise the platelet 
count 30 to 60 x 109/L. Cryoprecipitate is obtained from plasma or apheresis and contain high 
levels of fibrinogen and factor VIII. Cryoprecipitate can be used to replace low levels of 
fibrinogen (hypofibrinogenemia). Hypofibrinogenemia is regularly caused by coagulopathy 
and massive bleeding. If administration of cryoprecipitate is indicated, 10 units are typically 
transfused. The aim is to preserve the fibrinogen levels at minimally 100 mg/dL. A single unit 
of cryoprecipitate typically increase the fibrinogen levels from 5 to 10 mg/dL (19, 30). Calcium 
(Ca2+) is a metal ion which is essential for adequate thrombosis (7). For instance, calcium, and 
also the cation magnesium (Mg2+), are important for normal physiological function of factor 
IX. During massive blood transfusion, citrate consumes both calcium and magnesium, which 
can lead to hypomagnesemia and hypocalcaemia (37-39). Calcium gluconate and magnesium 
sulphate can be infused to treat hypocalcaemia and hypomagnesemia respectively (31). Voluven 
is a synthetic colloid composed of hydroxyethyl starch and can be used to prevent and treat 
hypovolemia (40). Ringers Lactate and normal saline are the most frequently utilized 
resuscitation crystalloids. These crystalloids can be used as maintenance or replacement fluids 
(31). 
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Transfusion ratios 
Many studies have investigated how different ratios of plasma and PRBC affect haemorrhagic 
patients (4, 13, 31, 32). It appears that high ratios of plasma to PRBC correlate to enhanced 
outcomes (4, 13). A ratio approaching 1:1 of plasma and PRBC has been proved to be associated 
with increased survival among seriously injured with traumatic bleeding in combat (4). Other 
studies have shown that ratios higher than 1:2 are correlated to increased survival and reduced 
mortality due to haemorrhage in patients receiving massive transfusions or suffering significant 
haemorrhage (24). A study from 2008 showed that a ratio of FFP:PRBC  ≥ 1:1.5 compared to 
<1.5 in patients treated with massive transfusions correlated to reduced mortality risk but a 
higher frequency of acute respiratory distress syndrome (ARDS) (41). Regarding massive 
transfusions, the evidence for the ratio 1:1:1 for PRBC:FFP:Platelets increases (31, 32). 
However, many of the studies proposing high ratios of plasma:PRBC are exclusively based on 
patients treated with massive transfusions which represent a small patient group in trauma 
centres. Although the data is convincing enough to confidently prove that high ratios from 1:2 
to 1:1 increase survival, a big share of the studies were retrospective and observational, and 
faced methodical and analytical difficulties. Lack of data and survival bias are some of the 
issues that contributed to aggravating circumstances. (32). It seems like many of the studies 
evaluating the effect of different plasma:PRBC ratios focus on FFP rather than FDP as plasma 
product (4, 13, 31, 32, 41). The usage of blood products like FDP and PRBC within the military 
has been studied, though the usage of FDP and PRBC within the emergency medical services 
has been studied in a limited extent (42).  
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Transfusion related complications 
Transfusions can be the difference between life and death, though blood transfusions are not 
performed without risk. Transfusion related complications can be divided into infectious and 
non-infectious, acute and delayed (19). One of the complications that can occur due to 
transfusions of blood products (especially apheresis platelets and plasma), is transfusion-related 
acute lung injury (TRALI) (24, 43, 44). TRALI is an acute complication and can be described 
as a “non-cardiogenic pulmonary edema causing acute hypoxemia that occurs within six hours 
of a transfusion and has a clear temporal relationship to the transfusion”. The oedema is caused 
by immune system activation. TRALI is a lethal complication and in the year of 2006 it 
contributed to more than 50 % of the deaths related to transfusion complications (19). Another 
condition that can occur due to multiple transfusions is acute respiratory distress syndrome 
(ARDS). ARDS can be described as a condiction which “is characterized by acute lung injury, 
noncardiogenic pulmonary edema, and severe hypoxia”. The oedema is caused by injury on the 
pulmonary epithelium and endothelium. ARDS is also a lethal complication and can lead to 
reduced lung function (45). Multiple organ dysfunction (MODS) is another transfusion related 
complication and can be caused by PRBC-transfusions (33). Sequential Organ Failure 
Assesment (SOFA) is one of many models that can be used to evaluate organ failure (46). Acute 
kidney injury (AKI) is a potential complication from transfusions and can be described as “a 
common clinical syndrome defined as a sudden onset of reduced kidney function manifested 
by increased serum creatinine or a reduction in urine output”. There are many different 
definitions for AKI and there are also different classification systems, where acute kidney injury 
network (AKIN) is one of them. AKIN is categorized into stage 1-3 depending on the severity 
where stage 3 is the most severe. AKIN stage is based on creatinine levels, urine output and 
need for renal replacement therapy (47, 48). 
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Inkosi Albert Luthuli Central Hospital 
Inkosi Albert Luthuli Central Hospital (IALCH), located in Durban, South Africa, is a highly 
specialized tertiary and quaternary governmental regional referral hospital. IALCH is the only 
quaternary facility in KwaZulu-Natal and the apex unit for a province covering an area of 
94,000 km2, with a population of 11.5 million inhabitants. The hospital is a specialised referral 
centre for complex patients requiring sub-specialist care and holds multiple surgical, medical, 
peri-operative, and mother and child domains with totally 864 beds. South Africa’s solely 
dedicated burns unit with 46 beds is also situated here. There are 6 intensive care units (ICU’s) 
in IALCH, namely: neonatal, paediatric, cardiothoracic, renal, neuro and trauma. The trauma 
ICU (TICU) is a level 1 trauma centre and has a total of 16 beds, half of them are ICU beds and 
the other half are high-care beds. The TICU and resuscitation unit at IALCH, two linked and 
cooperating trauma departments, are both tertiary health departments. These departments 
receive both paediatric and adult patients with serious and complex traumatic injuries via 
referral from surrounding hospitals or directly from scene in the entire region of KwaZulu-
Natal. The other regional hospitals all have small ICU’s but there is no other trauma specific 
ICU elsewhere than on IALCH.  
 
Since the TICU and resuscitation unit at IALCH are tertiary departments, exclusively patients 
with severe injuries are admitted. If a person in the region of KwaZulu-Natal is exposed to 
trauma, there are typically two ways the patient can be admitted to the resuscitation unit and 
TICU at IALCH. The first way is that the patient first is taken to a primary or secondary hospital 
(base hospital) or an out-patient clinic. If the patient is transported to this first care institution 
by ambulance, Ringers lactate, Saline and sometimes Voluven are used. At the arrival to the 
this first care institution the patient’s status is evaluated. If the injuries are too extensive or 
severe at this care institution, or if too severe complications occur, the patient will be 
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transported the by road ambulance or helicopter to IALCH. At the first care institution and 
during the transport to IALCH, FDP, PRBC, Ringers lactate, Saline and Voluven can be 
transfused. It is the first care institution that provide the road ambulance or helicopter with FPD 
and PRBC. Smaller health care institutions might only possess two to four units of blood for 
the entire institution. Except for referrals, the second way that patients can be admitted to the 
resuscitation unit and TICU at IALCH is directly from scene, which can occur if the severity 
of the injuries initially are considered to be too serious to be treated at a primary or secondary 
hospital. Regarding transfusions, haemorrhagic patients are typically transfused with FDP and 
PRBC in the ratio 1:1, but since the supply of FDP and PRBC often is limited, haemorrhagic 
patients sometimes will be transfused with other ratios than 1:1.  
 
At arrival to IALCH the patient first enters the resuscitation unit where the patient’s status is 
evaluated using ATLS. At the resuscitation unit the patient’s coagulation status is typically 
analysed by rotational thromboelastrometry (ROTEM) and blood samples in order to evaluate 
the need for further transfusions. For ROTEM the standard measurement method used is 
EXTEM. Depending on the patient’s circulation status, coagulation status, ROTEM results and 
blood samples, further administration with FDP, PRBC, thrombocytes, cryoprecipitate, 
calcium, magnesium, Ringers lactate, saline and/or Voluven can be carried through. Local 
memos based on guidelines like ATLS 10 are used to guide the transfusions and 
administrations. After management in the resuscitation unit the patient is referred to the TICU 
or the operation theatre if acute surgery is needed.  
 
Since March 2007, when this specialised unit opened, information about the patients admitted 
to the TICU at IALCH is recorded into a local database called the Medicom Databank. The 
database includes all trauma admissions to the TICU at IALCH and is hosted by the mentioned 
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health care institution. Approximately 250 patients are treated at the TICU at IALCH and 
recorded into the database annually. At IALCH, MEDITECH is the system used for electronical 
medical records. Patient information recorded before the arrival to IALCH can be stored in 
MEDITECH in the form of a short summary, a referral consultant form, scanned medical 
records and/or an ambulance form. Information about the treatment at IALCH is recorded in 
MEDITECH. The most relevant information is compiled into the database when the patient has 
been discharged from the trauma ICU at IALCH.  
Indications for transfusions at Inkosi Albert Luthuli Central Hospital 
Under this subheading the indications for transfusion at the resuscitation unit and trauma ICU 
at IALCH will be presented. If TEG is pathological, FDP is primarily used as treatment and 
secondarily platelets or cryoprecipitate. The indications for transfusion of FDP, PRBC and 
platelets at IALCH are illustrated in table 1. The FDP is produced by and purchased from Natal 
Bioproducts (NBI). Since the availability of platelets occasionally is limited and sometimes has 
to be transported long distances, FDP is intermittently administered instead of platelets when 
platelets are indicated. Cryoprecipitate shall be administered to patients with fibrinogen levels 
lower than 1 g/L and the aim is to reach fibrinogen levels of 2 g/L. Administration of calcium 
is indicated when the serum levels of ionized calcium are lower than 1 mmol/L. Finally, 
administration of magnesium is indicated when the plasma levels of magnesium is lower than 
0.75 mmol/L. 
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Table 1 Indications for transfusion of FDP, PRBC and platelets 
Indications for transfusion of FDP 
1. As a component in massive transfusions 
2. As an expander 
3. As a supplement when 2 litres of other fluids have been administered 
4. Present coagulopathy on ROTEM 
4a. Prolonged clotting time 
4b. Increased alpha-angle 
4c. Increased maximum clot firmness 
Indications for transfusion of PRBC 
1. As a component in massive transfusions 
2. Noted or suspected extensive bleeding 
3. Specific Hb-levels 
3a. Stable patients are transfused when Hb drops to 6-7 g/dL 
3b. For patients planned for surgery the aim is an Hb-level of approximately 9 g/dL 
3c. Throughout resuscitation during the first 24-48 h the aim is a Hb-level as close to 10 g/dL as possible 
3d. Patients treated with dialysis are transfused when Hb drops to 5 
Indications for transfusion of platelets 
1. As a component in massive transfusions 
2. Present coagulopathy on ROTEM 
2a. Decreased maximum amplitude 
2b. Decreased alpha-angle (if FDP has been transfused previously) 
3. Decreased platelet count 
3a. < 100 x 109 for neurosurgery 
3b. < 50 x 109 for other surgery than neurosurgery 
3c. < 20 x 109 in ICU if no active bleeding 
Aim 
The aim of the study is to investigate how different ratios of freeze-dried plasma and 
erythrocytes transfused to trauma patients during the initial patient care affect mortality, the 
number of days treated and transfusion related complications.  
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Research questions 
How do different ratios of FDP and PRBC transfused to trauma patients until 24 hours after 
admission to the trauma ICU affect mortality, the number of days treated at the trauma ICU at 
IALCH and the frequency of the following transfusion related complications: Acute Kidney 
Injury diagnosed with AKIN, Transfusion Related Acute Lung Injury (TRALI), Acute 
Respiratory Distress Syndrome (ARDS), and Multiple Organ Dysfunction Syndrome (MODS)? 
Theory 
As mentioned in the introduction section, it seems like no optimal ratio for FDP and PRBC has 
yet been confirmed. Higher ratios of plasma compared to PRBC seem to have benefits 
compared to lower ratios. In many hospitals, for example at the Sahlgrenska University Hospital 
in Gothenburg, Sweden, PRBC is administered before plasma in trauma patients. A theory is 
that early administration of FDP and higher ratios of FDP:PRBC transfused to trauma patients 
might correlate to more beneficial outcomes. 
Material and methods 
The study was a retrospective exploratory observational longitudinal descriptive analytical 
chart review conducted at the resuscitation unit and the trauma ICU at Inkosi Albert Luthuli 
Central Hospital, Durban, South Africa. Patients who had been treated at the resuscitation unit 
and/or TICU at IALCH between 2018-01-01 to 2019-08-15 and were transfused with FDP and 
PRBC were included. The patient data was collected from a local database (the Medicom 
Databank) and the electronic medical records system MEDITECH. Both the database and 
MEDITECH contained information written in English. The collected data was stored 
anonymised in an encrypted excel document. Eight weeks of time were dedicated to collect 
data for as many patients as possible. The data was collected along with David Karlsson, a 
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fellow medical student, who did research on the same topic but on different research questions. 
Before patients could be included, they were reviewed regarding the inclusion and exclusion 
criteria shown in table 2.  
Table 2 Inclusion & exclusion criteria 
Inclusion criteria 
Trauma patients admitted to the resuscitation unit at IALCH within 24h after injury 
Patients who at admission were between 18-80 years of age 
Patients treated at the resuscitation unit and/or trauma ICU between 2018-01-01 to 2019-08-15 
Patients transfused with FDP and PRBC before arrival to the resuscitation at IALCH or within the first 24 
hours after admission to IALCH 
Exclusion criteria 
Non-trauma patients 
Patients with thermal injuries covering 1 % or more of the total body surface area 
Patients with known diseases that affect coagulation (for example haemophilia and Von Willebrands 
disease) 
Patients who prior the trauma had been regularly treated with anticoagulants 
Patients with known pregnancy 
Patients declared brain dead before arrival at IALCH 
Patients with ISS 75 who expired due to other conditions than bleeding and coagulopathy 
Patients who are known to have been treated for another trauma within 2 weeks before current trauma 
injury 
Patients who expired within 72 hours after arrival where bleeding and coagulopathy were not present and 
did not contribute to the death 
 
The included patients were divided into 2 groups depending on the ratio of FDP and PRBC that 
had been transfused from injury until 24 hours after admission to IALCH, or alternatively the 
ratio of FDP and PRBC transfused from injury until the moment of expiration at IALCH if 
expiration occurred within 24 hours after admission to IALCH (table 3). 
Table 3 Grouping 
 
 
Except for data specific for the research questions, the standard trauma variables for exploratory 
retrospective trauma studies were included. The following data was extracted from the database 
and the electronic medical records and then recorded in the encrypted excel 
Group number A B 
Ratio FDP ≤ PRBC FDP > PRBC 
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document/proforma: sex, age, injury severity scale, date and time for injury and admission, 
survival and date for death or discharge. Also, the following laboratory measurements and vital 
parameters taken both at admission to IALCH and earliest possible subsequently to 24 hours 
after admission to IALCH were recorded in the excel document: pH, base excess, lactate, 
ionized calcium (only routinely recorded at arrival), body temperature, haemoglobin and 
platelets. Body temperature and pH was used to conclude if the patients had acidosis (pH ≤ 7,2 
was considered acidosis) and hypothermia (body temperature ≤ 36.0 °C was considered 
hypothermia). Furthermore, transfusions and treatment of the following products from injury 
until admission to IALCH and during the first 24 hours after admission to IALCH were 
recorded: FDP, PRBC, platelets, cryoprecipitate, calcium, magnesium, Ringers lactate (boluses 
but not maintenance treatment was recorded), Saline and Voluven. Whereas different notes in 
the medical records regarding amounts of transfused FDP and PRBC contained conflicting 
information or were defective, the amounts of FDP and PRBC that were considered most 
reasonable after reviewing and comparing the notes were recorded into the excel document. If 
no quantifiable amount or details were mentioned, no administrations were recorded and the 
corresponding cell was left empty in the proforma. If no information about transfusions prior 
to admission, no referral letters or no ambulance forms could be found, it was considered that 
no transfusion had been carried through before arrival to IALCH. Finally, presence of the 
following conditions stated in the database or medical records and the day the conditions 
occurred were recorded in the proforma: AKI diagnosed with AKIN, TRALI, ARDS, MODS, 
Ventilator Associated Pneumonia (VAP) and Sepsis. For the number of days treated and the 
day the conditions occurred, the day of admission is recorded as day 0. If necessary, additional 
information about the patients could be added in a comment column.  
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Statistical methods 
The acquired data was analysed through SPSS v 26.0 for Mac (IBM, Armonk NY, USA) to 
draw conclusions about how the different ratios of FDP and PRBC affect adverse events. The 
significance level was set to Significance level p < 0.05. The null hypothesis was stated as 
followed: there is no significant difference in mortality, the number of days treated or the 
frequency of transfusion related complications between the two groups. Further, the alternative 
hypothesis was stated in this way: there is a significant difference in mortality, the number of 
days treated or the frequency of morbidities between the three groups. Categorization of the 
number of days treated and the days of survival was made. Fisher’s Exact 2-Sided Test was 
used to analyse the mortality Pearson’s Chi-Squared Test was used to analyse the number of 
days treated. Analytical statistical tests were not applied on the transfusion related 
complications since the number of positive outcomes were too few to fulfil the tests’ 
assumptions. Fisher’s Exact 2-Sided Test and Independent-samples Mann-Whitney U test were 
used to analyse characteristics of the two ratio groups. No other subgrouping was made since 
only severe trauma cases were admitted to the resuscitation unit and TICU at IALCH which 
entailed that the studied population could be considered quite homogenous. 
Ethical considerations 
The study was conducted according to the UN’s declaration on human rights and the ethical 
principles of the Declaration of Helsinki. The local database (Medicom Databank) has been 
approved for retrospective observational studies by the Ethics Committee of the University of 
KwaZulu-Natal (BCA207-09). An application for approval of this study as a BCA207-09 
substudy was sent to The Research Committee of the University of KwaZulu-Natal and the 
approval was authorised. The data was stored anonymously in encrypted excel documents.  
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Results 
Sample statistics 
Under this subheading, characteristics of the two ratio groups and the entire study population 
will be demonstrated. Under the following subheadings in the result section, descriptive and 
analytical statistics related to the research questions will be illustrated. As described in the 
methods section, the study population was divided into two groups. Group A was administered 
with fewer or equal units of FDP compared to PRBC, while group B was administered with 
more units of FDP than PRBC. In total 73 patients were included. The distribution of the 
patients, gender and age characteristics among the two ratio groups are illustrated in table 4. 
Fisher's exact 2-sided test showed no significant difference of the gender distribution between 
the two groups (p = 0.782). Independent-samples Mann-Whitney U test showed no significant 
difference in distribution of age across group A and group B (p = 0.795).  
Table 4 Characteristics of the study population 
Group 
descriptions  
Group A B 
Ratio FDP ≤ PRBC FDP > PRBC 
Nr of patients 35 38 
Gender  
Female 7 (20.0%) 9 (23.7%) 
Male 28 (80.0%) 29 (76.3%) 
Age 
Continuous 
data 
Mean 35.86 36.18 
Median 34 34 
Minimum 18 18 
Maximum 65 73 
Categorised 
data 
18 – 29 12 (34.3%) 14 (36.8%) 
30 – 39 11 (31.4%) 8 (21.1%) 
40 – 49 8 (22.9%) 14 (36.8%) 
≥ 50 4 (11.4%) 2 (5.3%) 
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In the grouped bar chart in figure 1, the patients are categorised according to age and gender. 
 
Figure 1 Age according to gender 
 
In the grouped bar chart in figure 2, the patients are categorised according to ISS and gender. 
 
 
Figure 2 ISS according to gender. ISS = Injury severity score. 
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In the box plot in figure 3, ISS for the two ratio groups are illustrated. For group A there are 
three outliers, two with ISS 75 and one with ISS 64. Independent-samples Mann-Whitney U 
test showed no significant difference in distribution of ISS across group A and group B (p = 
0.619).  
 
Figure 3 ISS according to sample groups. ISS = Injury severity score. 
 
In table 5 below, blood parameters at arrival are illustrated. All blood parameters were missing 
for 2 patients in group A.  
Groups
IS
S
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ISS
Group A FDP = PRBC
Group B FDP > PRBC
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Table 5 Blood parameters at arrival 
Group 
descriptions 
Group nr A B Units 
Ratio FDP ≤ PRBC FDP > PRBC 
 
Nr of patients 33 38 
Base Excess  
Mean -6.155 -6.926 
mmol/L 
Minimum -24.0 -22.3 
Maximum 7.3 2.7 
25th percentile -9.250 -10.700 
50th percentile -7.000 -7.250 
75th percentile -2.150 -2.350 
Lactate  
Mean 5.388 5.200 
mmol/L 
Minimum 0.9 0.7 
Maximum 18.9 18.0 
25th percentile 3.150 2.125 
50th percentile 5.000 4.250 
75th percentile 6.600 7.425 
pH 
Mean 7.3052 7.2703 
 
Minimum 6.98 6.87 
Maximum 7.52 7.45 
25th percentile 7.2450 7.2200 
50th percentile 7.3200 7.2900 
75th percentile 7.3900 7.3525 
Ionized 
calcium 
Mean 1.0626 1.0730 
mmol/L 
Minimum 0.73 0.68 
Maximum 1.23 1.23 
25th percentile 1.04 1.01 
50th percentile 1.09 1.09 
75th percentile 1.12 1.15 
Haemoglobin  
Mean 8.767 10.242 
g/dL 
Minimum 5.5 4.9 
Maximum 12.4 16.2 
25th percentile 7.25 8.10 
50th percentile 8.90 10.35 
75th percentile 9.95 12.20 
Platelets 
Mean 173.47 176.84 
109/L 
Minimum 32 39 
Maximum 336 313 
25th percentile 127.75 113.25 
50th percentile 172.00 177.00 
75th percentile 205.50 227.25 
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Table 6 demonstrates the first blood parameters taken 24 hours after admission. The number of 
patients in table 6 are lower than in table 5 due to expiration of patients. Ionized calcium could 
not be found other than at arrival except for a few patients and is therefore not illustrated in 
table 6. 
Table 6 Blood parameters 24 hours after arrival 
Group 
descriptions 
Group nr A B Units 
Ratio FDP ≤ PRBC FDP > PRBC 
 
Nr of patients 30 36 
Base Excess 
Mean 0.800 2.331 
mmol/L 
Minimum -8.0 -16.8 
Maximum 7.9 9.2 
25th percentile -1.700 0.275 
50th percentile 1.650 2.700 
75th percentile 3.700 5.375 
Lactate 
Mean 1.987 2.408 
mmol/L 
Minimum 0.5 0.5 
Maximum 5.3 19.4 
25th percentile 1.200 1.025 
50th percentile 1.750 1.700 
75th percentile 2.325 2.625 
pH 
Nr of patients 30 35 
 
Mean 7.3870 7.4157 
Minimum 7.21 7.19 
Maximum 7.52 7.59 
25th percentile 7.3525 7.3800 
50th percentile 7.3950 7.4300 
75th percentile 7.4325 7.4600 
Haemoglobin 
Mean 8.820 8.717 
g/dL 
Minimum 5.5 2.7 
Maximum 12.4 12.3 
25th percentile 7.775 7.825 
50th percentile 8.450 8.750 
75th percentile 9.650 9.600 
Platelets 
Mean 119.77 122.39 
109/L 
Minimum 50 26 
Maximum 271 252 
25th percentile 95.50 99.25 
50th percentile 115.00 114.00 
75th percentile 144.00 143.00 
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In table 7 below, administered products from injury until arrival at IALCH are illustrated. In 
the medical records and the database, no records of administration of autotransfusion or 
administration of tranexamic acid, calcium and magnesium before arrival were found, therefore 
this was not presented in table 7. The minimum amount of each administered products in each 
group was 0.  
Table 7 Administered products from injury until arrival on IALCH 
Group 
descriptions 
Group nr A B Units 
Ratio FDP ≤ PRBC FDP > PRBC 
 
Nr of patients 35 38 
FDP 
Nr of patients 
administered 9 (25.7%) 17 (44.7%) Units  
(1 unit = 
200 ml) 
Mean 0.66 1.82 
Maximum 6 13 
PRBC 
Nr of patients 
administered 12 (34.3%) 17 (44.7%) Units  
(1 unit = 
300 ml 
Mean 0.93 1.47 
Maximum 6 9 
Platelets 
Nr of patients 
administered 1 (2.9%) 2 (5.3%) Units  
(1 unit = 
250 ml) 
Mean 0.03 0.08 
Maximum 1 2 
Cryoprecipi-
tate 
Nr of patients 
administered 1 (2.9%) 1 (2.6%) 
Units Mean 0.23 0.26 
Maximum 8 10 
Ringers 
Lactate 
Nr of patients 
administered 18 (51.4%) 24 (63.2%) Units  
(1 unit = 
1 000 ml 
Mean 1.557 1.829 
Maximum 5 10 
Voluven 
Nr of patients 
administered 10 (28.6%) 10 (26.3%) Units  
(1 unit = 
500 ml) 
Mean 0.486 0.539 
Maximum 3.0 4.0 
NaCl 
Nr of patients 
administered 1 (2.9%) 2 (5.3%) Units  
(1 unit = 
1 000 ml) 
Mean 0.006 0.066 
Maximum 0.2 1.5 
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In table 8, administered products during the first 24 hours after admission to IALCH are 
illustrated. The minimum amount of each administered products in each group was 0. For one 
patient, there was a note in the medical records informing that the patient had been administered 
with crystalloids. The amount and type of crystalloids transfused were not registered, therefore 
no data for Ringers Lactate and NaCl was recorded for this patient, thereby resulting in missing 
data regarding Ringers Lactate and NaCl for this patient. For this reason, percentage for the 
number of patients administered is not illustrated for Ringers Lactate and NaCl. Percentiles for 
the administered products are only demonstrated when at least 50 % of the patients in both ratio 
groups have been administered with the product.  
 
Table 8 Administered products during the first 24 hours after admission to IALCH 
Group 
descriptions 
Group nr A B Units 
Ratio FDP ≤ PRBC FDP > PRBC 
 
Nr of patients 35 38 
FDP 
Nr of patients 
administered 29 (82.9%) 35 (92.1%) 
Units  
(1 unit = 
200 ml) 
Mean 2.60 4.55 
Maximum 7 14 
25th percentile 2.00 2.00 
50th percentile 2.00 4.00 
75th percentile 4.00 6.00 
PRBC 
Nr of patients 
administered 30 (85.7%) 27 (71.1%) 
Units  
(1 unit = 
300 ml) 
Mean 2.843 1.842 
Maximum 7 8 
25th percentile 2.00 0.00 
50th percentile 2.00 1.00 
75th percentile 4.00 3.00 
Platelets 
Nr of patients 
administered 10 (28.6%) 13 (34.2%) Units  
(1 unit = 
250 ml) 
Mean 0.31 0.39 
Maximum 2 2 
Cryoprecipi-
tate 
Nr of patients 
administered 7 (20.0%) 7 (18.4%) 
Units Mean 1.77 1.55 
Maximum 10 10 
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Calcium 
Nr of patients 
administered 16 (45.7%) 22 (57.9%) Ampoules (1 ampoule 
= 10 ml 10 
% Ca) 
Mean 1.54 2.42 
Maximum 6 12 
Magnesium 
Nr of patients 
administered 21 (60.0%) 16 (42.1%) Ampoules (1 Ampoule 
= 2 ml 50% 
Mg) 
Mean 1.63 1.53 
Maximum 4 6 
Ringers 
Lactate 
Nr of patients 
administered 25 29 (76.3%) 
Units  
(1 unit = 
1 000 ml 
Mean 1.2176 1.4316 
Maximum 7.50 4.00 
25th percentile 0.000 0.375 
50th percentile 1.000 1.000 
75th percentile 2.000 2.125 
Voluven 
Nr of patients 
administered 16 (45.7%) 18 (47.4%) Units  
(1 unit = 
500 ml) 
Mean 0.760 0.816 
Maximum 3.0 4.0 
NaCl 
Nr of patients 
administered 1 1 (2.6%) Units  
(1 unit = 
1 000 ml) 
Mean 0.06 0.03 
Maximum 2 1 
 
In table 9, administration of tranexamic acid and autotransfusion during the entire length of stay 
is illustrated. 
Table 9 Autotransfusions and administration of tranexamic acid at IALCH 
Group 
descriptions 
Group nr A B 
Ratio FDP ≤ PRBC FDP > PRBC 
Nr of patients 35 38 
Autotransfusion Nr of patients administered 2 (5.7%) 3 (7.9%) 
Tranexamic acid Nr of patients administered 6 (17.1%) 3 (7.9%) 
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In table 10, the number of units of FDP and PRBC transfused from injury until 24 hours after 
admission to IALCH, are illustrated. 
Table 10 Administered FDP and PRBC from injury until 24 hours after admission 
Group 
descriptions 
Group nr A B Units 
Ratio FDP ≤ PRBC FDP > PRBC 
 
Nr of patients 35 38 
FDP 
Mean 3.26 6.37 
Units  
(1 unit = 200 
ml) 
Maximum 7 15 
25th percentile 2.00 4.00 
50th percentile 2.00 5.50 
75th percentile 5.00 8.00 
PRBC 
Mean 3.771 3.316 
Units  
(1 unit = 300 
ml 
Maximum 7.0 11.0 
25th percentile 2.00 1.00 
50th percentile 4.00 3.00 
75th percentile 6.00 5.00 
 
Illustrated in table 11 below are the frequencies of consequences of trauma and complications 
due to trauma care among the two ratio groups during the entire length of stay. Fisher's Exact 
significance 2-sided test generated the p-value 0.60 when analysing hypothermia at arrival. 
Table 11 Consequences of trauma and complications due to trauma care during the entire length of stay 
Group 
descriptions 
Group nr A B 
Ratio FDP ≤ PRBC FDP > PRBC 
Nr of patients 35 38 
Hypothermia 
at arrival 
Yes 13 (37.1%) 6 (15.8%) 
No 22 (62.9%) 32 (84.2%) 
Hypothermia 
after 24 ha 
Yes 0 (0%) 3 (8.3%) 
No 30 (100%) 33 (91.7%) 
Acidosis at 
arrivalb 
Yes 7 (20.6%) 8 (21.1%) 
No 27 (79.4%) 30 (78.9%) 
Acidosis 
after 24 ha 
Yes 0 (0%) 1 (2.9%) 
No 30 (100%) 34 (97.1%) 
VAPc 
Yes 6 (17.1%) 4 (10.5%) 
No 29 (82.9%) 34 (89.5%) 
Sepsis 
Yes 7 (20.0%) 8 (21.1%) 
No 28 (80.0%) 30 (78.9%) 
a. Patients missing because of death or missing data in medical records 
b. Patients missing because of missing data in medical records 
c. VAP = Ventilator associated pneumonia 
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Mortality 
In this section, descriptive and analytical statistics related to the following research question 
will be demonstrated: how do different ratios of FDP and PRBC transfused to trauma patients 
until 24 hours after admission to the trauma ICU affect mortality. In group A, 11 (31.4%) of 
the 35 patients expired. In group B, 11 (28.9%) of the 38 patients expired. In table 12, 
descriptive analytical statistics of expired patients are presented. Independent-samples Mann-
Whitney U test showed no significant difference in distribution of ISS among expired patients 
across group A and group B (p = 0.171). As mentioned in the text describing figure 3, two 
patients in group A had ISS 75. Both these patients expired at the day of arrival. Fischer’s Exact 
2-sided Test was used to compare the two mortality time intervals 0-7 days and 8-14 days 
between for the two group ratio groups. This test generated the p-value 0.152. 
Table 12 Mortality 
Group 
descriptions 
Group nr A B Fischer’s Exact 
Test (2-sided) Ratio FDP ≤ PRBC FDP > PRBC 
Nr of expired 
patients 11 11  
ISSa 
Minimum 26 18 
 
Maximum 75 51 
25th percentile 27.00 18.00 
50th percentile 43.00 35.00 
75th percentile 64.00 50.00 
Days of 
survival  
Mean 9.82 6.91 
 
Minimum 0 1 
Maximum 51 19 
25th percentile 1.00 2.00 
50th percentile 5.00 8.00 
75th percentile 16.00 9.00 
24-hour 
mortality 
Expired (<24 hb) 5 (45.5%) 2 (18.2%) 
 
Expired (>24 hc) 6 (54.5%) 9 (81.8%) 
Days of 
survival 
(Categorised) 
0-7 7 (63.6%) 5 (45.5%) 
0.152 
8-14 1 (9.1%) 5 (45.5%) 
≥15 3 (27.3%) 1 (9.1%)  
a. ISS = Injury Severity Score  
b. Expired within 24 hours after arrival 
c. Expired 24 hours after arrival or later 
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The number of days treated 
In this section, descriptive and analytical statistics related to the following research question 
will be demonstrated: how do different ratios of FDP and PRBC transfused to trauma patients 
until 24 hours after admission to the trauma ICU affect the number of days treated at the trauma 
ICU at IALCH. All the results presented in this section are based on surviving patients only. In 
table 13, descriptive and analytical statistics for surviving patients are presented. Independent-
samples Mann-Whitney U test showed no significant difference in distribution of ISS among 
surviving patients across group A and group B (p = 0.151). Pearson’s Chi-Squared Exact 
Significance (2-sided) Test was used to analyse the number of days treated with categorised 
time intervals. This test generated the p-value 0.277. 
Table 13 Number of days treated for surviving patients 
Group 
descriptions 
Group nr A B Pearsons Chi-
Squared Exact 
Significance 
(2-sided) Test 
Ratio FDP ≤ PRBC FDP > PRBC 
Nr of patients 24 (100%) 27 (100%) 
ISSa 
Minimum 9 10  
Maximum 41 68  
25th percentile 16.25 18.00  
50th percentile 25.00 30.00  
75th percentile 35.50 43.00  
Number of 
days treated  
Mean 20.08 15.04  
Minimum 2 2  
Maximum 130 47  
25th percentile 8.25 4.00  
50th percentile 11.00 11.00  
75th percentile 24.50 24.00  
Number of 
days treated 
(Categorised) 
1-7 4 (16.7%) 10 (37.0%) 
0.277b 8-14 9 (37.5%) 8 (29.6%) 
≥15 11 (45.8%) 9 (33.3%) 
a. ISS = injury Severity Score 
b. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.59. 
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The number of days treated for all surviving patients in the study population are illustrated in 
the histogram in figure 4. Among the surviving patients, the lowest number of days treated were 
2 days and the highest number of days treated were 130 days. 
 
Figure 4 Number of days treated for surviving patients 
The box plot in figure 5 illustrates ISS for surviving patients depending on the number of days 
treated categorised into time intervals. 
 
Figure 5 ISS for surviving patients according to the number of days treated. ISS = Injury severity score 
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Transfusion related complications 
In this section, descriptive and analytical statistics related to the following research question 
will be demonstrated: how do different ratios of FDP and PRBC transfused to trauma patients 
until 24 hours after admission to the trauma ICU correlate to the frequency of AKI, TRALI, 
ARDS and MODS. In table 14, transfusion related complications that occurred 24 hours after 
arrival or later among patients that survived more than 24 hours are presented. Multiple patients 
developed AKI within 24 hours after admission and therefore they are not included in this chart. 
No patients developed TRALI, ARDS or MODS within 24 hours after admission. The 
frequencies of the transfusion related complications were too few in order to apply analytical 
statistic tests. One case of TRALI was suspected and considered likely and therefore registered, 
however TRALI was not definitely confirmed. 
Table 14 Transfusion related complications that occurred 24 hours  
after arrival or later among patients that survived >24 hours 
Group 
descriptions 
Group nr A B 
Ratio FDP ≤ PRBC FDP > PRBC 
AKIN 
Yes 3 (13.0%) 1 (3.6%) 
No 20 (87.0%) 27 (96.4%) 
TRALI 
Yes 0 (0%) 0 (0%) 
No 30 (100%) 36 (100%) 
ARDS 
Yes 1 (3.3%) 0 (0%) 
No 29 (96.7%) 36 (100%) 
MODS 
Yes 2 (6.7%) 3 (8.3%) 
No 28 (93.3%) 33 (91.7%) 
AKIN = Acute Kidney Injury Network 
TRALI = Transfusion Related Acute Lung Injury 
ARDS = Acute Respiratory Distress Syndrome 
MODS = Multiple Organ Dysfunction Syndrome   
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Discussion 
Result oriented considerations 
Introduction to discussion and discussion of sample statistics 
In this section, the most important findings will be mentioned and the characteristics of the 
samples will be discussed. As shown in the result section, there were no significant differences 
regarding how the two different ratios of FDP and PRBC affect mortality and the number of 
days treated. The number of transfusion related complications were too few in order to perform 
analytical statistical tests. Under the following sections below, each research question will be 
discussed further. Regarding the sample characteristics, an important factor is that the two 
sample groups should be quite homogenous. The reason for this line of argument is that many 
other factors than the ratio of FDP and PRBC might affect the outcomes investigated. Slighter 
differences were found in some of the collected variables. These variables and other important 
variables will accordingly be discussed. Regarding ISS, there was no significant difference 
between the two ratio groups (p = 0.619). Figure 2 (ISS according to gender) shows that most 
patients, namely 35 patients, had ISS 26-50 and fewest patients, namely 9 patients, had ISS 51-
75. This figure also shows that the distribution of gender among the different ratio groups is 
quite equal. As described for figure 3 (ISS according to sample groups), two patients in group 
A had ISS 75, the highest ISS possible, which correlates to increased risk for mortality. 
Concerning age and gender, no significant difference in analytical statistical tests were found 
(p = 0.782 respectively p = 0.795). Figure 1 (Age according to gender) shows even distribution 
of gender among different age categories.  
 
Regarding haemoglobin at arrival, table 5 (Blood parameters at arrival) shows that the mean 
value for group A is 8.767 g/dL while the mean value for group B is 10.242 g/dL. In addition 
to the mean value, all percentiles are also higher for group B than for group A. This might 
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reasonably be a contributing factor to the division of the ratio groups. In group A, a bigger share 
of the patients most likely fulfilled the indications for transfusion of PRBC, thereby 
contributing to more or equal units of transfused PRBC compared to FDP. Table 6 (Blood 
parameters 24 hours after arrival) shows that both mean values and percentiles of haemoglobin 
24 hours after arrival are equalized, likely due to greater shares of PRBC transfusions in group 
A compared to group B. Concerning administration of tranexamic acid, which can contribute 
to decreased haemorrhage, table 9 (Autotransfusions and administration of tranexamic acid at 
IALCH) shows that 6 patients in group A were administered with tranexamic acid while 3 
patients in group B were administered. Accordingly, twice as many patients were transfused in 
group A compared to group B, however the absolute numbers were too few to apply analytical 
statistical tests. Finally, regarding hypothermia, table 11 (Consequences of trauma and 
complications due to trauma care during the entire length of stay) shows that 13 patients in 
group A and 6 patients in group B had hypothermia at arrival. Fisher's Exact significance 2-
sided test showed no significant difference between the two ratio groups regarding hypothermia 
at arrival (p = 0.60). Regarding hypothermia after 24 hours, 0 patients in group A and 3 patients 
in group B were positive. As described, there sometimes were trends pointing towards 
differences in relevant factors, however none of these trends showed statistical significance. 
This fact therefore enables comparison of the two ratio groups regarding the research questions. 
Mortality 
The results related to mortality are illustrated in table 12 (Mortality). As previously mentioned, 
there was no significant difference regarding how the two different ratios of FDP and PRBC 
affect mortality. The number of expired patients in group A was 11 (31.4 %) out of 35, and in 
group B the number of expired patients was 11 (28.9 %) out of 38. Regarding ISS for the expired 
patients, all percentiles and the maximum value were higher for group A than for group B. In 
group A, two patients had ISS 75, and both these patients expired at the day of arrival. In group 
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A, totally 5 patients (45.5 % of the expired patients) expired within the first 24 hours after 
arrival, compared to 2 patients (18.2 % of the expired patients). As shown in table 12, for group 
A, 7 patients expired within 0-7 days, 1 patient within 8-14 days and 3 patients after 15 days or 
more. For group B, the number for the different intervals enumerated in the same order are 5, 
5 and 1. Since expiration related to or affected by coagulopathy, haemorrhage and transfusion 
was considered unlikely ≥ 15 days after admission, the patients that expired ≥ 15 days after 
arrival were not included when Fischer’s exact test was used to analyse mortality. Seen to the 
descriptive statistics, a bigger share of the patients in group A expired early (within 0-24 hours 
after admission and during the first 7 days after admission) compared to group B. A possible 
explanation to this might be the two patients with ISS 75 in group A with poor survival 
prognosis.  
 
As mentioned in the background, most of the studies investigating plasma:PRBC ratios are 
based on data from patients receiving massive transfusion and FFP as the choice of blood 
plasma. Therefore, articles that focus on FFP:PRBC ratios are applied in the discussion. A meta-
analysis published 2013 investigated how different ratios of plasma:PRBC in trauma patients 
receiving massive transfusions affect 30-day mortality. This study showed that plasma:RPBC 
ratios of 1:2 or higher significantly reduced the mortality in relation to ratios lower than 1:2. 
However, ratios of 1:1 were not more advantageous than 1:2 ratios (49). Zink et al. also showed 
that ratios of FFP:PRBC higher than 1:2 correlated to higher survival rates compared to ratios 
lower than 1:2 (50). Many studies have shown similar results as those mentioned above. It 
seems like ratios higher than 1:1 have been studied in limited extent (4, 13, 24, 31, 32, 41). 
Maegele et al. however, compared ratios FFP:PRBC ratios < 1:1, 1:1 and > 1:1 among patients 
that received massive transfusions and proved that ratios higher than 1:1 increased 6-hour, 24 
hour and 30-day survival compared to lower ratios (51). 
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The number of days treated 
As mentioned earlier, there was no significant difference regarding how the two different ratios 
of FDP and PRBC affect the number of days treated. As mentioned in the results section, all 
results concerning the number of days treated are based on data for surviving patients only. The 
results related to the number of days treated are illustrated in table 13 (Number of days treated 
for surviving patients), figure 4 (Number of days treated for surviving patients) and figure 5 
(ISS for surviving patients according to the number of days treated). Regarding ISS for the 
surviving patients, all ISS percentiles were higher for group B compared to group A, however 
there was no significant difference across the two groups (p = 0.151). As shown in figure 5, ISS 
also increases in relation to longer lengths of stays for the entire study population, which is a 
reasonable and logical tendency since higher ISS correlate to more severe injuries. The median 
value for the number of days treated for surviving patients was 11 for both group A and group 
B. In group A, only 16.7 % of the surviving patients were treated for 1-7 days, while 37.0 % of 
the surviving patients in group B were treated for 1-7 days. Group B also had relatively fewer 
patients treated for 8-14 days and ≥15 days than group A (see table 13). Seen to these descriptive 
statistics in this study population, higher ratios of FDP and PRBC seemed to correlate with 
fewer days of treatment. This trend is contradictory since all ISS percentiles were higher for 
group B than for group A. However, there was no significant difference between the two ratio 
groups regarding the number of days treated and ISS. In the previously mentioned study by 
Maegele et al. ratios of FFP:PRBC higher than 1:1 increased the length of stay and the number 
of ventilator days (51). Similar findings were made in a study by Sambasivan et al. where 
FFP:PRBC ratios higher than 1:2 correlated with fewer ICU-free days and ventilator-free days 
(52).  
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Transfusion related complications 
The results concerning transfusion related complications are illustrated in table 14 (Transfusion 
related complications that occurred 24 hours). Regarding the transfusion related complications, 
the number of patients positive with AKI, TRALI, ARDS and MODS ≥ 24 hours after 
admission were too few to perform any statistical tests. Multiple patients developed AKIN 
before arrival or during the first 24 hours after admission. Since the patients were allocated to 
a specific ratio group first 24 hours after arrival, it would only be relevant to conduct statistical 
tests on the transfusion related complications that occurred ≥24 hours after admission. An 
important fact to consider is that, especially for AKI and MODS, there are multiple other risk 
factors than transfusions for these syndromes (48) (53). AKI and MODS were the complications 
with highest frequency in this study, however it is not unlikely that these cases could have been 
generated by other aetiologies than transfusions. Murad et al. showed that for patients receiving 
massive transfusions, ratios of FFP:PRBC greater than 1:3 correlate to lower frequency of 
multiorgan failure, though the quality of the findings was low (54). The study by Maegele et 
al. instead discovered that the frequency of organ failure was higher for trauma patients 
transfused with FDP:PRBC ratios of 1:1 compared to higher and lower ratios (51).  
 
No cases of TRALI and one case of suspected ARDS were recorded. In one study, the frequency 
of adverse reactions due to plasma transfusion was set to one reaction per 300 to 1,700 
administrations (55). A study investigating risk factors for TRALI, showed that plasma and 
platelets were the blood products that were most likely to cause TRALI (56). Regarding ARDS, 
high ratios of FFP to PRBC has been suggested to correlate with higher risk of developing 
ARDS (57). However, another study suggests that high ratios of FFP:PRBC is not correlated to 
either TRALI or ARDS, even for patients who did not receive massive transfusions (58). 
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Methodological considerations 
As mentioned in the introduction, studies on transfusion ratios can be associated with 
methodological difficulties. Because of ethical and practical reasons, prospective trials are 
challenging to conduct, thereby advocating retrospective studies. This study was a retrospective 
chart review based on information retrieved from medical records and a database. In medical 
records, information important for the patient care might be recorded properly whereas 
information important for study purpose might not be recorded adequately or not at all, since 
this is not the primary purpose for the medical records. For some parameters there was 
sometimes missing or conflicting data in the medical records. In addition, scanned documents 
could sometimes be hard to interpret. This occasionally led to difficulties in estimating the exact 
amount or number of units of fluids, blood products and medicine that had been administered. 
This could lead to difficulties or possibly even incorrectness in estimating which ratio of FDP 
and PRBC patients had received. Lack of data, especially from referral letters or ambulance 
forms, could possibly result in that a patient who actually had been transfused with FDP and 
PRBC was not included in the study since no information about transfusions could be found. 
This possibility of under coverage would mean that the study population is not completely 
representative. Occasionally, the date but not the exact time of injury was known. In these cases, 
a basic assessment based on other parameters was made to evaluate if the patient most likely 
was admitted to IALCH within 24 hours after injury or not. Regarding diagnoses, the diagnoses 
were mentioned in reports and discharge summaries, though no ICD codes could be retrieved. 
This could possible lead to under coverage of complications. Despite these issues, there was 
generally adequate and correct data to be retrieved for many of the patients. Still, overall the 
quality of the collected data is not as high as preferable.  
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Except for data related matters, methodological and analytical factors must be concerned. The 
aim of the study was to investigate how different ratios of transfused FDP and PRBC affect 
different outcomes. However, there are multiple other factors than the ratio of FDP:PRBC that 
affect the outcomes, for example the type of trauma, the severity of the injury or injuries, time 
from trauma until treatment, management of the trauma, physiological capacity and reserves, 
unexpected complications etc. Futility is a term which alludes to that the patient’s condition 
and prognosis are so poor that the patient will expire regardless option of treatment. Futility can 
be a difficult factor to manage when studying mortality since too high frequency of futility 
might conceal the effect that the preferred independent variable (transfusion ratios in this study) 
has on mortality. Exclusion criteria were designed to prevent inclusion of patients with futility. 
However, it is hard to formulate exclusion criteria that completely prevent all futility, especially 
without risking excluding patients without futility. For example, two patients with ISS 75 were 
included in group A and both these patients expired at the day of arrival. Another complicated 
factor to consider is that after the surviving patients have been treated at the TICU at IALCH, 
they are either transferred to a primary or secondary hospital or to their home. After the transfer 
it is not possible to track the number of days treated, mortality or transfusion related 
complications. For practical and economic reasons, patients with poor prognosis and high 
probability of near expiration or patients with palliative treatment can be transferred to their 
local hospital for terminal treatment. In these cases, possible positive outcomes cannot be 
recorded. One of the included patients had bad prognosis and high probability to expire and 
was sent back to base hospital. Since this study was retrospective, the patients were not 
randomised to a specific ratio. Therefore, there is a probability that hidden confounders could 
contribute to which amount and ratios of FDP and PRBC that the patients receive. In advance, 
a confounder considered possible, was that severely injured patients with major haemorrhage 
and coagulopathy would receive massive transfusions and therefore receive equal units of FDP 
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and PRBC. Consequently, these patients would end up in group A and likely have worse 
outcomes than the other groups because of poorer initial condition and prognosis. However, 
this scenario was not realized in this study. A possible confounder though, is that FDP 
occasionally is administered instead of cryoprecipitate. Which of these products that were used 
clinically could possibly affect which ratio group a patient finally was allocated to. Lack of 
blood products could likely have the same effect.  
 
The duration demanded for collecting data was greater than expected, resulting in a smaller 
study population than planned. As described earlier there are sometimes signs of trends or 
differences that are not statistically significant. If the number of participants would have been 
greater significant differences might would have been detected if there were any.  
 
Strengths in this study are that many variables were collected which might increase the 
probability of detecting confounders. Another strength is that only two persons collected data 
for a short period of time, thereby reducing the risk for methodical errors.  
  
  
44 
Suggestion on further studies 
Since there are few studies investigating how different ratios of FDP and PRBC affect mortality, 
the number of days treated and transfusion related complications, there is great potential for 
research within this field. In future studies comparing ratios of FDP and PRBC there are 
multiple factors that can be considered and improved. One of the most important factors might 
be to investigate a significantly greater study population in order to achieve greater power. 
Accurate power calculations should be made so that sufficient number of participants can be 
included. Considerably longer time for data collection could also be preferable in order to obtain 
greater numbers. Instead of a retrospective study design a prospective study design would be 
eligible. The advantages for a prospective study design are that recording would be more 
reliable and adapted for study purpose and that confounders and factors that might affect the 
outcomes are easier to track. During the initial phase of the trauma where the number of 
transfused FDP and PRBC affect which ratio group the patient is allocated to, no cryoprecipitate 
should be used since it has similar effects on coagulation as FDP has. Patients might also be 
tracked for a longer time period and over different health care institutions regarding the 
outcomes, alternatively only short-term outcomes could be investigated. The number of patients 
in the different ratio groups would preferably also be equal in numbers to increase the power.  
Conclusions 
No significant differences between the groups were found. Therefore, no general conclusions 
regarding FDP:PRBC ratios for trauma patients could be drawn. Additional studies with greater 
numbers of patients will be required to further evaluate the impact of different ratios of FDP 
and PRBC transfused to trauma patients. 
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Populärvetenskaplig sammanfattning 
Rubrik: Frystorkad plasma och ogynnsamma utfall 
Underrubrik: En journalstudie som undersöker förekomsten av ogynnsamma utfall hos 
traumapatienter i förhållandet till proportionerna av frystorkad plasma och röda blodkroppar 
som patienterna behandlats med 
Sammanfattning: I denna studie undersöktes behandlingseffekten av olika förhållanden av 
röda blodkroppar och frystorkad plasma som givits till traumapatienter. Röda blodkroppar och 
plasma kan utvinnas från blodet från blodgivare. Plasma kan beskrivas som den del av blodet 
som innehåller koagulationsfaktorer, vilka är ytterst viktiga för att blodets normala förmåga att 
koagulera (levra sig). För att kunna förvara och sedan använda plasman, kan plasman tillredas 
och behandlas på olika sätt. Traditionellt används färskfrusen plasma, men det finns också en 
annan form av plasma i pulverform som heter frystorkad plasma (på engelska freeze-dried 
plasma: FDP). De stora fördelarna med FDP är att den kan förvaras i omgivningstemperatur, 
har lång hållbarhet, är lätt att transportera och endast behöver blandas med sterilt vatten innan 
den ska ges till en patient. Användningen av FDP inom sjukvården har varit begränsad men 
dess många fördelar har ökat intresset för användning inom sjukhusvård och ambulanssjukvård. 
Traumapatienter kan ibland behöva behandlas med både FDP och röda blodkroppar för att 
ersätta förlorad blodvolym och behandla försämrad koagulationsförmåga, blödning och brist på 
röda blodkroppar. När traumapatienter är allvarligt skadade och stora mängder blodprodukter 
behövs brukar man eftersträva att ge patienten lika många enheter FDP som röda blodkroppar. 
Det är dock omtvistat vilket förhållande av FDP och röda blodkroppar som är mest optimalt. 
Syftet med denna studie var att undersöka hur olika förhållanden av FDP och röda blodkroppar 
påverkar olika förutbestämda faktorer, nämligen: antalet vårddagar, dödlighet och förekomsten 
av komplikationer från blodprodukterna. Studien genomfördes på en traumavårdsenhet på 
Inkosi Albert Luthuli Central Hospital i Durban (IALCH) i Durban, Sydafrika, där man sedan 
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flera år tillbaka använt FDP. Data samlades in från en lokal databas och medicinska journaler 
på traumavårdsenheten på IALCH. Patienterna delades in i två olika grupper beroende på vilket 
förhållande av FDP och röda blodkroppar de behandlats med. Patienterna i grupp A fick färre 
enheter FDP än röda blodkroppar eller lika många enheter FDP som röda blodkroppar, medan 
patienterna i grupp B fick fler enheter FDP än röda blodkroppar. Totalt inkluderades 73 
patienter i studien. De statistiska tester som användes för att undersöka frågeställningarna 
visade inga signifikanta skillnader mellan grupperna, alltså går det utifrån denna studie inte att 
dra några slutsatser kring vilket förhållande av FDP och röda blodkroppar som är mest optimalt 
för traumapatienter. Ytterligare studier med större patientantal behöver genomföras för att 
ytterligare utvärdera effekten av olika förhållanden av FDP och röda blodkroppar som 
traumapatienter behandlas med.  
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